BR112018000841A8 - Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites - Google Patents
Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélitesInfo
- Publication number
- BR112018000841A8 BR112018000841A8 BR112018000841A BR112018000841A BR112018000841A8 BR 112018000841 A8 BR112018000841 A8 BR 112018000841A8 BR 112018000841 A BR112018000841 A BR 112018000841A BR 112018000841 A BR112018000841 A BR 112018000841A BR 112018000841 A8 BR112018000841 A8 BR 112018000841A8
- Authority
- BR
- Brazil
- Prior art keywords
- renewal
- satellite cell
- receptor stimulating
- stimulating agent
- agent
- Prior art date
Links
- 239000002269 analeptic agent Substances 0.000 title abstract 3
- 230000004069 differentiation Effects 0.000 title abstract 2
- 230000003835 satellite cell maintenance involved in skeletal muscle regeneration Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 abstract 2
- 102000017309 5-Hydroxytryptamine 1B receptors Human genes 0.000 abstract 1
- 108050005281 5-Hydroxytryptamine 1B receptors Proteins 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000009756 muscle regeneration Effects 0.000 abstract 1
- 210000001665 muscle stem cell Anatomy 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
- C12N5/0659—Satellite cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562193714P | 2015-07-17 | 2015-07-17 | |
EP16305444 | 2016-04-15 | ||
PCT/EP2016/066948 WO2017013031A1 (en) | 2015-07-17 | 2016-07-15 | 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018000841A2 BR112018000841A2 (pt) | 2018-09-11 |
BR112018000841A8 true BR112018000841A8 (pt) | 2022-11-22 |
Family
ID=55808532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018000841A BR112018000841A8 (pt) | 2015-07-17 | 2016-07-15 | Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites |
Country Status (9)
Country | Link |
---|---|
US (2) | US10493046B2 (pt) |
EP (2) | EP3799873A1 (pt) |
JP (1) | JP7000321B2 (pt) |
CN (1) | CN108348486A (pt) |
AU (1) | AU2016296205B2 (pt) |
BR (1) | BR112018000841A8 (pt) |
CA (1) | CA2992161A1 (pt) |
MX (1) | MX2018000657A (pt) |
WO (1) | WO2017013031A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018000841A8 (pt) | 2015-07-17 | 2022-11-22 | Pasteur Institut | Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites |
US11013830B2 (en) | 2015-11-20 | 2021-05-25 | Institut Pasteur | 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential |
US20210284615A1 (en) * | 2016-07-22 | 2021-09-16 | Qingeng Li | Vortioxetine analogue and use and preparation thereof |
JP2021008409A (ja) * | 2019-06-28 | 2021-01-28 | 佐藤製薬株式会社 | 筋再生促進剤 |
CN110988351B (zh) * | 2019-09-05 | 2023-10-20 | 首都医科大学附属北京安定医院 | 血管细胞黏附分子在制备抑郁症诊断治疗相关产品的用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
US6860042B2 (en) | 2002-07-19 | 2005-03-01 | Walker-Dawson Interests, Inc. | Excavation system employing a jet pump |
RS20050944A (en) | 2003-05-22 | 2008-06-05 | Nerviano Medical Sciences S.R.L., | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
DE202006007482U1 (de) | 2006-05-10 | 2006-07-20 | Sentner, Thomas | Leuchtmöbel |
CN101506188B (zh) * | 2006-06-22 | 2014-01-15 | 雷蒙特亚特特拉维夫大学有限公司 | 作为具外周系统限制活性药物的五羟色胺再摄取抑制剂 |
FR2903984B1 (fr) | 2006-07-24 | 2008-10-03 | Genfit Sa | Derives d'imidazolones substitues, preparation et utilisations |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
EP2120944A1 (en) | 2006-12-22 | 2009-11-25 | Medestea Internazionale S.p.A. | A novel use of antidepressant compounds and related compositions |
TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
GB0907350D0 (en) * | 2009-04-29 | 2009-06-10 | Myotec Therapeutics Ltd | Methods |
TR201821217T4 (tr) | 2010-06-23 | 2019-01-21 | Hanmi Science Co Ltd | Tirozin kinaz aktivitesinin inhibisyonu için yeni kaynaşmış pirimidin türevleri. |
US9248185B2 (en) * | 2011-06-16 | 2016-02-02 | President And Fellows Of Harvard College | Methods of increasing satellite cell proliferation |
GB201120259D0 (en) | 2011-11-24 | 2012-01-04 | Univ Gent | Allogeneic immune response control |
WO2014066672A1 (en) * | 2012-10-26 | 2014-05-01 | Beech Tree Labs, Inc. | Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin |
GEP201706739B (en) * | 2012-12-13 | 2017-09-25 | H Lundbeck As | Compositions comprising vortioxetine and donepezil |
US20160101093A1 (en) | 2013-05-21 | 2016-04-14 | Jason B. Wynberg | Methods for the treatment of premature ejaculation |
CN104736526B (zh) * | 2013-09-12 | 2016-04-20 | 杭州普晒医药科技有限公司 | 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途 |
BR112018000841A8 (pt) * | 2015-07-17 | 2022-11-22 | Pasteur Institut | Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites |
EP3362058B1 (en) | 2015-10-14 | 2021-09-01 | Institut Pasteur | 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction |
US11013830B2 (en) | 2015-11-20 | 2021-05-25 | Institut Pasteur | 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential |
AU2017295038B2 (en) | 2016-07-15 | 2022-09-22 | Centre Hospitalier Sainte Anne Paris | 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair |
-
2016
- 2016-07-15 BR BR112018000841A patent/BR112018000841A8/pt not_active Application Discontinuation
- 2016-07-15 EP EP20209038.7A patent/EP3799873A1/en active Pending
- 2016-07-15 CN CN201680053683.4A patent/CN108348486A/zh active Pending
- 2016-07-15 EP EP16739465.9A patent/EP3324952B1/en active Active
- 2016-07-15 AU AU2016296205A patent/AU2016296205B2/en not_active Ceased
- 2016-07-15 MX MX2018000657A patent/MX2018000657A/es unknown
- 2016-07-15 CA CA2992161A patent/CA2992161A1/en not_active Abandoned
- 2016-07-15 US US15/744,345 patent/US10493046B2/en active Active
- 2016-07-15 JP JP2018521709A patent/JP7000321B2/ja active Active
- 2016-07-15 WO PCT/EP2016/066948 patent/WO2017013031A1/en active Application Filing
-
2019
- 2019-10-31 US US16/669,626 patent/US11344515B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2992161A1 (en) | 2017-01-26 |
BR112018000841A2 (pt) | 2018-09-11 |
AU2016296205A1 (en) | 2018-02-01 |
JP2018521140A (ja) | 2018-08-02 |
EP3799873A1 (en) | 2021-04-07 |
US20180200207A1 (en) | 2018-07-19 |
AU2016296205B2 (en) | 2021-11-11 |
US10493046B2 (en) | 2019-12-03 |
CN108348486A (zh) | 2018-07-31 |
EP3324952A1 (en) | 2018-05-30 |
US20200060999A1 (en) | 2020-02-27 |
US11344515B2 (en) | 2022-05-31 |
MX2018000657A (es) | 2018-09-06 |
JP7000321B2 (ja) | 2022-02-10 |
EP3324952B1 (en) | 2020-12-16 |
WO2017013031A1 (en) | 2017-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017000864A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
BR112018000841A8 (pt) | Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites | |
CO2017011851A2 (es) | Compuestos novedosos | |
CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
PE20200494A1 (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson | |
DOP2017000025A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
UY35682A (es) | Anticuerpos anti-activina a y usos de los mismos | |
BR112012021275A2 (pt) | composição, formulação, e, uso de uma formulação. | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
CL2012003226A1 (es) | Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas. | |
CL2012002037A1 (es) | Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca | |
PH12016502307A1 (en) | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
EA201791875A1 (ru) | Комбинированная композиция тезофензина и бета-блокатора | |
BR112017012581A2 (pt) | tratamento de degeneração da retina com o uso de células progenitoras | |
CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
EA201692278A1 (ru) | Комбинации формотерола и будесонида для лечения хобл | |
BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
MX2016010177A (es) | Composicion adyuvante anticancerosa que contiene promotor de la expresion de rip3 como principio activo, metodo para la deteccion de adyuvante anticanceroso que potencia la sensibilidad al farmaco anticanceroso mediante la estimulacion de la expresion de rip3 y metodo para controlar la sensibilidad del farmaco anticanceroso. | |
EA201891439A1 (ru) | Трициклические соединения и их композиции в качестве ингибиторов киназ | |
BR112017009848A2 (pt) | combinação, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica. | |
CL2017002304A1 (es) | Métodos para tratar enfermedades |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: INSTITUT PASTEUR (FR) ; CENTRE HOSPITALIER SAINTE ANNE PARIS (FR) ; INSTITUT GUSTAVE-ROUSSY (FR) ; UNIVERSITE DE PARIS (FR) |
|
B25D | Requested change of name of applicant approved |
Owner name: INSTITUT PASTEUR (FR) ; CENTRE HOSPITALIER SAINTE ANNE PARIS (FR) ; INSTITUT GUSTAVE-ROUSSY (FR) ; UNIVERSITE PARIS CITE (FR) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |